Peginterferon lambda-1a, a new therapeutic for hepatitis c infection, from bench to clinic

Journal of Clinical and Translational Hepatology

Volumn 1, Issue 2, 2013, Pages 116-124

  Andersen, Henrik ^a   Meyer, Jeff ^a   Freeman, Jeremy ^a   Doyle, Sean E ^a   Klucher, Kevin ^a   Miller, Dennis M ^a   Hausman, Diana ^a   Hillson, Jan L ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Discovery; HCV; Interferon

Indexed keywords

EID: 84994659407     PISSN: 22250719     EISSN: 23108819     Source Type: Journal    
DOI: 10.14218/JCTH.2013.00014     Document Type: Review

References (45)

1. Lavanchy D. The global burden of hepatitis C. Liver Int 2009;29:74–81.
2. World Health Organization. Prevention & control of viral hepatitis infection: framework for global action. Available at: www.who.int/csr/disease/hepatitis/ GHP_framework.pdf, accessed October 2013.
3. Sulkowski MS, Cooper C, Hunyady B, Jia J, Ogurtsov P, Peck-Radosavljevic M, et al. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol 2011;8:212–223.
4. Ghany M, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guidelines by the American Association for the Study of Liver Diseases. Hepatology 2011;54:1433–1444.
5. Qin H, Li H, Zhou X, Feng F, Shen Y, Tan H, et al. Safety of telaprevir for chronic hepatitis C virus infection: a meta-analysis of randomized controlled trials. Clin Drug Investig 2012;32:665–672.
6. Maasoumy B, Port K, Markova AA, Serrano BC, Rogalska-Taranta M, Sollik L, et al. Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PLoS One 2013;8:e55285.
7. Teixeira R, Nascimento Yde A, Crespo D. Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions. Braz J Infect Dis 2013;17:194–204.
8. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003;4:63–68.
9. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, et al. IFN-ls mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003;4:69–77.
10. Donnelly RP, Kotenko SV. Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res 2010;30:555–564.
11. Kotenko SV. IFN-ls. Curr Opin Immunol 2011;23:583–590.
12. Donnelly RP, Dickensheets H, O’Brien TR. Interferon-lambda and therapy for chronic hepatitis C virus infection. Trends Immunol 2011;32:443–450.
13. Doyle SE, Schreckhise H, Khuu-Duong K, Henderson K, Rosler R, Storey H, et al. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 2006;44:896–906.
14. Witte K, Gruetz G, Volk HD, Looman AC, Asadullah K, Sterry W, et al. Despite IFN-l receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun 2009;10:702– 714.
15. Sommereyns C, Paul S, Staeheli P, Michiels T. IFN-lambda (IFN-l) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 2008;4:e1000017.
16. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, MacDonald MR, et al. Interferons a and l inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006; 131:1887–898.
17. Yin Z, Dai J, Deng J, Sheikh F, Natalia M, Shih T, et al. Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells. J Immunol 2012;189:2735–2745.
18. Byrnes-Blake KA, Pederson S, Klucher KM, Anderson-Haley M, Miller DM, Lopez-Talavera JC, et al. Pharmacokinetics and pharmacodynamics of pegylated interferon lambda-1 in cynomolgus monkeys. J Interferon Cytokine Res 2012;32:198–206.
19. Robek MD, Boyd BS, Chisari FV. Lambda interferon inhibits hepatitis B and C virus replication. J Virol 2005;79:3851–3854.
20. Zhu H, Butera M, Nelson DR, Liu C. Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication. Virol J 2005;2:80.
21. Baker DE. Pegylated interferons. Rev Gastroenterol Disord 2001;1:87–99.
22. Kozlowski A, Charles SA, Harris JM. Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrugs 2001;15:419–429.
23. Grace MJ, Cutler D. Pegylating IFNs at his-34 improves the in vitro antiviral activity through the JAK/STAT pathway. Antivir Chem Chemother 2004;15: 287–297.
24. Grace M, Youngster S, Gitlin G, Sydor W, Xie L, Westreich L, et al. Structural and biologic characterization of pegylated recombinant IFN-alpha2b. J Interferon Cytokine Res 2001;21:1103–1115.
25. Foser S, Schacher A, Weyer KA, Brugger D, Dietel E, Marti S, et al. Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS). Protein Expr Purif 2003;30: 78–87.
26. Harris JM, Herati RM. Preparation and use of poly-ethylene glycol propionaldehyde. US Patent 5,252,714. 1993.
27. Byrnes-Blake KA, Freeman JA, Rapalus L, Pederson S, Fontana D, LopezTalavera JC, et al. Pharmacokinetics of peg-interferon lambda (pegIFNl) following fixed dosing in treatment-naive hepatitis C subjects (single-dose interim data from a dose-ranging Phase 2a study). Hepatology 2010;52: 720A–721A.
28. Muir AJ, Shiffman ML, Zaman A, Yoffe B, de la Torre A, Flamm S, et al. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 2010;52: 822–832.
29. Hausman DF, Freeman JA, Souza SM, Nesterov IA, Zhang T. A Phase 1, randomized, blinded, placebo-controlled, single-dose, dose-escalation study of PEG-interferon lambda (PEG-rIL-29) in healthy subjects. Global Antiviral J 2007;3(Suppl 2):71–72.
30. Maher SG, Sheikh F, Scarzello AJ, Romero-Weaver AL, Baker DP, Donnelly RP, et al. IFN-a and IFN-l differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol Ther 2008;7:1109–1115.
31. Freeman JA, Zhang T, Holdren MS, Hausman DF. PEG-interferon lambda (PEG-rIL-29): translation of in vitro preclinical data to clinical results. J Hepatol 2008;48(Suppl 2):S294.
32. Bannai H, Tatsumi M, Kohase M, Onishi E, Yamazaki S. Pharmacokinetic study of a human recombinant interferon (Re-IFN-alpha A) in cynomolgus monkeys by 29–59 oligoadenylate synthetase assay. Jpn J Med Sci Biol 1985; 38:113–124.
33. Bannai H. Comparison of pharmacokinetic behaviors of two human interferons (Lb-IFN-alpha and Re-IFN-alpha A) in cynomolgus monkeys by 29–59 oligoadenylate synthetase assay. Jpn J Med Sci Biol 1986;39:185–198.
34. Miller DM, Klucher KM, Freeman JA, Hausman DF, Fontana D, Williams DE. Interferon lambda as a potential new therapeutic for hepatitis C. Ann N Y Acad Sci 2009;1182:80–87.
35. Muir AJ, Lawitz E, Ghalib RH, Sussman NL, Anderson F, Everson GT, et al. Pegylated interferon lambda (PEG-IFN l) Phase 2 dose-ranging, active-controlled study in combination with ribavirin (RBV) for treatment-naïve HCV patients (genotypes 1, 2, 3 or 4): safety, viral response, and impact of IL-28B host genotype through week 12. Hepatology 2010;52:715A.
36. Zeuzem S, Arora S, Bacon B, Box T, Charlton M, Diago M, et al. Peginterferon lambda-1a compared to peginterferon alfa-2a in treatment-naive patients with HCV genotype 2 or 3: first SVR24 results from EMERGE Phase IIB. J Hepatol 2012;56(Suppl 2):S5–S6.
37. Muir A, Hillson J, Gray T, Xu D, Ishak L, Freeman J, et al. Peginterferon lambda-1a (Lambda) compared to peginterferon alfa-2a (alfa) in treatment-treatment-naive patients with HCV genotypes 1 or 4: SVR24 results from EMERGE Phase 2b. Hepatology 2012;56(Suppl):299A. naive
38. Mordstein M, Neugebauer E, Ditt V, Jessen B, Rieger T, Falcone V, et al. Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J Virol 2010;84:5670–5677.
39. Mordstein M, Kochs G, Dumoutier L, Renauld JC, Paludan SR, Klucher K, et al. Interferon-l contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog 2008;4:e1000151.
40. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399–401.
41. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461: 798–801.
42. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105–1109.
43. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-a and ribavirin therapy. Nat Genet 2009;41:1100–1104.
44. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010;139:120–129.
45. Muir AJ, Srinivasan S, Sapra S, Dimitrova D, Hillson JL, Lopez-Talavera JC. Peginterferon lambda-1a is less likely to induce clinically significant neuropsychiatric symptoms during the treatment of chronic hepatitis C virus infection, compared to peginterferon alfa-2a. Hepatology 2012;56(Suppl): 578A–579A.